Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent.~2. Male and female patients with a body weight ≥ 10 kg.~3. Diagnosis of Still's disease.~4. If currently on glucocorticoid treatment, a stable dose for at least 1 week prior to randomization.~5. If currently on methotrexate treatment, a stable dose for at least 8 weeks prior to randomization.~6. Active disease.~7. Female patients of childbearing potential must use an effective method of contraception during the study (abstinence being a possible option) as well as present a negative pregnancy test prior to randomization.~8. Negative interferon-gamma release assay or Purified protein derivative ( PPD) test within 2 months prior to randomization. If not available, a test should be performed at day of randomization.~Exclusion Criteria:~1. Diagnosis of Still's disease more than 6 months prior to randomization.~2. Previous randomization into this study.~3. Participation in another concurrent clinical interventional study within 30 days of randomization.~4. Treatment with an investigational drug within 5 half-lives prior to randomization.~5. Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.~6. Use of the following therapies prior to randomization:~   * Narcotic analgesics within 24 hours prior to randomization.~  * Dapsone or etanercept within 3 weeks prior to randomization.~  * Intraarticular, intramuscular or intravenous administration of glucocorticoids or intravenous immunoglobulin (Ig) within 4 weeks prior to randomization.~  * Intravenous Ig with proven Still's disease modifying effect, leflunomide, infliximab or adalimumab within 8 weeks prior to randomization.~  * Thalidomide, cyclosporine, mycophenolate mofetil, 6-mercaptopurine, azathioprine, cyclophosphamide, chlorambucil or any other immunosuppressant within 12 weeks prior to randomization.~  * Tocilizumab within 12 weeks prior to randomization or any other immunomodulatory medication within 4 half-lives prior to randomization~  * Rituximab within 26 weeks prior to randomization.~7. Live vaccines within 1 month prior to randomization.~8. Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection.~9. Clinical evidence of liver disease or liver injury.~10. Presence of severe renal function impairment.~11. Presence of neutropenia.~12. Presence or suspicion of MAS at baseline.~13. A diagnosis of MAS within the last 2 months prior to randomization.~14. History of malignancy within 5 years.~15. Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra).~16. Pregnant or lactating women.~17. Foreseeable inability to cooperate with given instructions or study procedures.~18. Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with IMP.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anakinra (Type: EXPERIMENTAL): 2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
- Placebo (Type: PLACEBO_COMPARATOR): Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).